title: Ursodeoxycholic acid for treatment of fatty liver disease and dyslipidemia in morbidly obese patients.
abstract: Bile acids have recently been identified as major integrators of hepatic fatty acid and triglyceride metabolism. We explored potential mechanism(s) of action of ursodeoxycholic acid (20 mg/kg/day in 3 weeks) in 40 morbidly obese patients (mean BMI >40 kg/m(2)) with suggested fatty liver disease awaiting bariatric surgery. At follow-up half a year after surgery, patients had decreased their BMI by approximately 10 kg/m(2), which resulted in significant improvements of liver function tests, insulin sensitivity and glucose tolerance.
authors.affiliation: Institute of Medicine, Department of Internal Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. hanns-ulrich.marschall@gu.se
authors.forename: Hanns-Ulrich
authors.initials: HU
authors.lastname: Marschall
authors.forename: Martin
authors.initials: M
authors.lastname: Wagner
authors.forename: Gernot
authors.initials: G
authors.lastname: Zollner
authors.forename: Peter
authors.initials: P
authors.lastname: Fickert
authors.forename: Caroline
authors.initials: C
authors.lastname: Lackner
authors.forename: Anders
authors.initials: A
authors.lastname: Thorell
authors.forename: Michael
authors.initials: M
authors.lastname: Trauner
mesh_terms: D000328:Adult; D050171:Dyslipidemias / Q000150:complications* / Q000188:drug therapy*; D005234:Fatty Liver / Q000150:complications* / Q000188:drug therapy*; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007333:Insulin Resistance; D008297:Male; D009767:Obesity, Morbid / Q000150:complications*; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
chemical_list: D014580:Ursodeoxycholic Acid